263 related articles for article (PubMed ID: 17089217)
21. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
[TBL] [Abstract][Full Text] [Related]
25. Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.
Illsinger S; Lücke T; Hartmann H; Mengel E; Müller-Forell W; Donnerstag F; Das AM
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S321-5. PubMed ID: 19894140
[TBL] [Abstract][Full Text] [Related]
26. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome.
Grewal SS; Wynn R; Abdenur JE; Burton BK; Gharib M; Haase C; Hayashi RJ; Shenoy S; Sillence D; Tiller GE; Dudek ME; van Royen-Kerkhof A; Wraith JE; Woodard P; Young GA; Wulffraat N; Whitley CB; Peters C
Genet Med; 2005 Feb; 7(2):143-6. PubMed ID: 15714083
[TBL] [Abstract][Full Text] [Related]
28. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
29. Regression of ventriculomegaly following medical management of a patient with Hurler syndrome.
Liang J; Singhal A
J Neurosurg Pediatr; 2016 May; 17(5):537-9. PubMed ID: 26745646
[TBL] [Abstract][Full Text] [Related]
30. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
[TBL] [Abstract][Full Text] [Related]
31. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
Kloska A; Bohdanowicz J; Konopa G; Tylki-Szymńska A; Jakóbkiewicz-Banecka J; Czartoryska B; Liberek A; Wegrzyn A; Wegrzyn G
Am J Med Genet A; 2005 Dec; 139(3):199-203. PubMed ID: 16283671
[TBL] [Abstract][Full Text] [Related]
32. Enzyme replacement therapy in 12 patients with MPS I-H/S with homozygous p.Leu490Pro mutation.
Arora RS; Mercer J; Thornley M; Tylee K; Wraith JE
J Inherit Metab Dis; 2007 Oct; 30(5):821. PubMed ID: 17570076
[TBL] [Abstract][Full Text] [Related]
33. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.
Wraith JE
Expert Opin Pharmacother; 2005 Mar; 6(3):489-506. PubMed ID: 15794739
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.
D'Aco K; Underhill L; Rangachari L; Arn P; Cox GF; Giugliani R; Okuyama T; Wijburg F; Kaplan P
Eur J Pediatr; 2012 Jun; 171(6):911-9. PubMed ID: 22234477
[TBL] [Abstract][Full Text] [Related]
35. Decreased corneal opacity and improved vision in a patient with mucopolysaccharidosis I (Hurler-Scheie) treated with enzyme replacement therapy (laronidase, Aldurazyme).
Cáceres-Marzal C; García-Reymundo M; Solana J; de Arévalo B; Vaquerizo J; Galán E
Am J Med Genet A; 2008 Jul; 146A(13):1768-70. PubMed ID: 18546328
[No Abstract] [Full Text] [Related]
36. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
[TBL] [Abstract][Full Text] [Related]
37. Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I.
Brooks DA
Expert Opin Biol Ther; 2002 Dec; 2(8):967-76. PubMed ID: 12517274
[TBL] [Abstract][Full Text] [Related]
38. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.
Gabrielli O; Clarke LA; Bruni S; Coppa GV
Pediatrics; 2010 Jan; 125(1):e183-7. PubMed ID: 20026495
[TBL] [Abstract][Full Text] [Related]
39. Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement. therapy.
Castorina M; Antuzzi D; Richards SM; Cox GF; Xue Y
Clin Exp Obstet Gynecol; 2015; 42(1):108-13. PubMed ID: 25864295
[TBL] [Abstract][Full Text] [Related]
40. Laronidase for the treatment of mucopolysaccharidosis type I.
Clarke LA
Expert Rev Endocrinol Metab; 2011 Nov; 6(6):755-768. PubMed ID: 30780865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]